Ovid Therapeutics Hosts Educational Webinar on Angelman Syndrome and OV101 Development Program Oct 22, 2020 1:00 PM EDT Click here for webcast
Press Releases Year None202020192018201720162015 Aug 25, 2020 Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Aug 10, 2020 Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Aug 05, 2020 Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020 Jul 23, 2020 Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome Jul 13, 2020 Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
